Oramed Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, ORMP, Oramed Pharmaceuticals Inc, priceseries

Oramed Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
8.89
Close
8.58
High
9.07
Low
8.48
Previous Close
8.93
Daily Price Gain
-0.35
YTD High
14.77
YTD High Date
Jan 3, 2022
YTD Low
7.52
YTD Low Date
Jan 24, 2022
YTD Price Change
-5.31
YTD Gain
-38.23%
52 Week High
31.54
52 Week High Date
Nov 3, 2021
52 Week Low
7.20
52 Week Low Date
Mar 8, 2021
52 Week Price Change
0.84
52 Week Gain
10.85%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 20. 2017
6.44
May 17. 2017
8.00
19 Trading Days
24.22%
Link
LONG
Sep 13. 2017
8.94
Sep 29. 2017
9.90
12 Trading Days
10.70%
Link
LONG
Apr 4. 2019
3.61
Apr 16. 2019
3.93
8 Trading Days
8.75%
Link
LONG
Jun 5. 2019
3.21
Jul 1. 2019
3.46
18 Trading Days
7.71%
Link
LONG
Jul 15. 2019
3.35
Jul 30. 2019
3.69
11 Trading Days
10.24%
Link
LONG
Nov 25. 2019
2.84
Dec 27. 2019
5.26
22 Trading Days
85.20%
Link
LONG
Jul 14. 2020
3.59
Jul 27. 2020
3.95
9 Trading Days
10.16%
Link
LONG
Nov 24. 2020
2.78
Dec 16. 2020
4.16
15 Trading Days
49.59%
Link
LONG
Jan 21. 2021
4.58
Feb 22. 2021
9.94
21 Trading Days
117.14%
Link
LONG
Apr 21. 2021
9.22
May 10. 2021
10.65
13 Trading Days
15.48%
Link
LONG
Jun 4. 2021
12.09
Jun 15. 2021
13.51
7 Trading Days
11.72%
Link
LONG
Jul 23. 2021
14.40
Jul 27. 2021
15.35
2 Trading Days
6.60%
Link
LONG
Oct 25. 2021
22.92
Nov 12. 2021
25.91
14 Trading Days
13.05%
Link
Company Information
Stock Symbol
ORMP
Exchange
NasdaqCM
Company URL
http://www.oramed.com
Company Phone
011 972-2-566-0001
CEO
Nadav Kidron
Headquarters
-
Business Address
HI-TECH PARK 2/4 GIVAT-RAM, PO BOX 39098, JERUSALEM, ISRAEL 91390
Sector
-
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001176309
About

Oramed Pharmaceuticals, Inc. engages in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in Jerusalem, Israel.

Description

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading